#USA #Chicago #Clinical Trials #Semaglutide #Alzheimer's Association

Alzheimer's Association Responds to Oral Semaglutide Phase 3 Results

The Alzheimer's Association has recently expressed its disappointment regarding the preliminary outcomes of the Phase 3 clinical trials for the oral semaglutide treatment. The trials, named evoke and evoke+, did not succeed in proving a statistically significant reduction in the progression of Alzheimer's disease, a result that comes as a letdown for many in the medical community and families affected by this devastating condition.

Joanne Pike, DrPH, the president and CEO of the Alzheimer's Association, remarked on the findings, stating, “While these results are not what we had hoped for, they will still significantly contribute to our understanding of Alzheimer's disease.” This sentiment reinforces the association's commitment to advancing research despite setbacks.

The trials focused on measuring the efficacy of an oral version of semaglutide specifically for early-stage symptomatic Alzheimer's disease. Despite the lack of impactful results, Pike emphasized the importance of data gathered from clinical trials, noting that they are vital in pushing forward our comprehension of this complex disease. Every piece of information gleaned from these studies is crucial in shaping future clinical trials and therapeutic approaches.

Both trials involved over 3,800 participants aged between 55 and 85 years, all diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s, categorized as stages 3 and 4 of the disease. While the treatment showed improvements in certain biomarkers associated with Alzheimer's within both studies, it failed to translate those improvements into a delay in disease progression.

Maria C. Carrillo, Ph.D., the scientific chief and medical affairs head at the Alzheimer's Association, added, “These findings will assist us in refining our understanding of this class of medications.” Carrillo acknowledged the complexities surrounding the medication, noting that it’s essential to keep exploring how these drugs can be employed differently in future studies.

The Alzheimer’s treatment landscape is continually evolving, with strong prospects on the horizon. An annual review published in early 2025 revealed that there are currently 182 active clinical trials assessing 138 new drug candidates for Alzheimer’s. To support these initiatives, the Alzheimer’s Association provides strategic funding through its “Part the Cloud” program, which aims to accelerate promising Alzheimer’s therapies into clinical evaluation.

Given the consensus that effective treatment and prevention of Alzheimer's disease is likely to hinge on a personalized combination of multiple interventions, the association remains resolute in its commitment to exploring various therapeutic avenues.

For individuals experiencing early-stage Alzheimer’s, there are approved treatment options available. The Alzheimer’s Association urges those impacted to consult their healthcare providers about these choices and consider participation in ongoing clinical trials. More information can be accessed on the Alzheimer’s Association’s TrialMatch website.

The Alzheimer’s Association is eager to delve deeper into the recent trial findings and anticipates discussions at the upcoming Alzheimer’s Clinical Trials Conference (CTAD) scheduled for December. This event will likely provide further context and analysis of the trials, ensuring that all insights can be integrated into ongoing research efforts.

In conclusion, the Alzheimer’s Association remains devoted to combating this illness, emphasizing research, expert collaboration, and continued exploration of innovative treatment strategies. The organization envisions a future where Alzheimer's disease may be effectively managed, and perhaps one day eradicated, paving the way for a world free from dementia's burdens. For more information, visit alz.org or call 800.272.3900.